Honour Essence Trading

Honour Essence Trading Limited is a key subsidiary of Hutchmed, a global biopharmaceutical company specializing in the discovery and development of targeted therapies for oncology and immunological diseases. The company serves as a primary entity for managing intellectual property and commercial rights for Hutchmed's portfolio of small molecule inhibitors. Its core assets include fruquintinib, a highly selective inhibitor of VEGFR 1, 2, and 3, and surufatinib, which targets VEGFR, FGFR1, and CSF-1R to inhibit tumor angiogenesis and promote immune response. Through its parent organization, the company has successfully commercialized multiple products in China and is expanding its global footprint through strategic partnerships with Takeda, AstraZeneca, and Eli Lilly. The company's pipeline also features savolitinib, a selective MET inhibitor developed in collaboration with AstraZeneca for MET-driven lung and gastric cancers. Honour Essence Trading plays a critical role in the corporate structure that supports Hutchmed's transition into a fully integrated global biopharmaceutical leader.